Evidence map›Paper›PMID 41584330›Full record

ArticleActa pharmaceutica Sinica. B2026

pH-Activatable engineered nanoparticle-based selective hexokinase 2 degrader provokes GSDME-dependent pyroptosis for cancer therapy.

Linlin Gong, Shasha Li, Jiahui Sun, Kunhong Liu, Simeng Wang, Meiju Ji, Peng Hou, Li Yan, Dan Yang, Dechun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linlin GongResearch & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen 518057, China.
Shasha LiResearch & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen 518057, China.
Jiahui SunResearch & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen 518057, China.
Kunhong LiuResearch & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen 518057, China.
Simeng WangKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Meiju JiKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Peng HouKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Li YanInstitute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.
Dan YangDepartment of Pharmaceutical Sciences, School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an 710021, China.
Dechun LiuResearch & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen 518057, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis targeting chimeras (PROTACs) technology has been developed as an exquisite promising approach for targeted protein degradation by hijacking the cellular ubiquitin-proteasome system (UPS). However, traditional PROTACs often suffer from insufficient tumor accumulation, unfavorable membrane penetration, and always-on biological activity, limiting their antitumor performance. Herein, we report a novel pH-activatable engineered nanoparticle-based selective hexokinase 2 degrader (Nano-PROTACs) for cancer therapy. Nano-PROTACs were constructed by conjugating PEI-based PROTACs to amphiphilic nanoparticles

Indexed as

Aerobic glycolysisCancer therapyHexokinase 2NanoparticleNano-PROTACsPolyethyleneiminePyroptosisTargeted protein degradation

Identifiers

PMID41584330
PMCPMC12828081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.